10月10日，迈威生物盘中下跌2.05%，截至10:57，报46.41元/股，成交2.13亿元，换手率2.22%，总市值 185.45亿元。 资金流向方面，主力资金净流出3052.38万元，特大单买入1024.10万元，占比4.80%，卖出2514.43万 元，占比11.80%；大单买入5522.22万元，占比25.91%，卖出7084.27万元，占比33.23%。 迈威生物今年以来股价涨129.75%，近5个交易日跌9.36%，近20日跌14.40%，近60日涨46.27%。 今年以来迈威生物已经5次登上龙虎榜，最近一次登上龙虎榜为9月2日。 资料显示，迈威(上海)生物科技股份有限公司位于中国(上海)自由贸易试验区蔡伦路230号2幢105室香港 铜锣湾希慎道33号利园1期19楼1928室，成立日期2017年5月12日，上市日期2022年1月18日，公司主营 业务涉及治疗用生物制品的研发、生产与销售。主营业务收入构成为：销售商品99.91%，提供劳务 0.09%。 迈威生物所属申万行业为：医药生物-化学制药-化学制剂。所属概念板块包括：AI医药、眼科概念、抗 癌治癌、抗癌药物、创新药等。 截至6月30日，迈威 ...

分红方面，吉贝尔A股上市后累计派现4.76亿元。近三年，累计派现2.96亿元。 责任编辑：小浪快报 吉贝尔所属申万行业为：医药生物-化学制药-化学制剂。所属概念板块包括：创新药、抗癌药物、生物 医药、抗癌治癌、高血压防治等。 截至6月30日，吉贝尔股东户数6003.00，较上期减少17.68%；人均流通股33221股，较上期增加 21.47%。2025年1月-6月，吉贝尔实现营业收入4.55亿元，同比增长4.90%；归母净利润1.49亿元，同比 增长22.38%。 资金流向方面，主力资金净流出372.05万元，特大单买入0.00元，占比0.00%，卖出140.04万元，占比 3.74%；大单买入738.20万元，占比19.73%，卖出970.21万元，占比25.93%。 吉贝尔今年以来股价涨59.41%，近5个交易日跌2.43%，近20日跌10.01%，近60日涨17.60%。 资料显示，江苏吉贝尔药业股份有限公司位于江苏省镇江市高新技术产业开发园区，成立日期2001年11 月13日，上市日期2020年5月18日，公司主营业务涉及专业从事药品研发、生产、销售。主营业务收入 构成为：利可君片72.72%，尼群洛 ...

10月9日，以岭药业盘中上涨2.01%，截至13:31，报16.21元/股，成交2.03亿元，换手率0.92%，总市值 270.82亿元。 以岭药业所属申万行业为：医药生物-中药Ⅱ-中药Ⅲ。所属概念板块包括：创新药、抗癌药物、抗癌治 癌、中药、幽门螺杆概念等。 截至6月30日，以岭药业股东户数17.01万，较上期减少8.18%；人均流通股8093股，较上期增加8.91%。 2025年1月-6月，以岭药业实现营业收入40.40亿元，同比减少12.26%；归母净利润6.69亿元，同比增长 26.03%。 分红方面，以岭药业A股上市后累计派现39.54亿元。近三年，累计派现13.37亿元。 机构持仓方面，截止2025年6月30日，以岭药业十大流通股东中，香港中央结算有限公司位居第四大流 通股东，持股1759.21万股，相比上期减少567.82万股。南方中证500ETF（510500）位居第五大流通股 东，持股1239.65万股，相比上期增加176.50万股。汇添富中证中药ETF（560080）位居第十大流通股 东，持股384.98万股，相比上期减少43.25万股。 责任编辑：小浪快报 资金流向方面，主力资金净流入5 ...

10月9日，益方生物盘中下跌2.03%，截至13:04，报30.48元/股，成交1.85亿元，换手率1.42%，总市值 176.28亿元。 截至6月30日，益方生物股东户数9790.00，较上期减少7.28%；人均流通股40990股，较上期增加 7.85%。2025年1月-6月，益方生物实现营业收入1916.38万元，同比增长28.85%；归母净利润-1.19亿 元，同比增长44.25%。 益方生物今年以来股价涨129.17%，近5个交易日跌9.61%，近20日跌29.22%，近60日跌4.00%。 机构持仓方面，截止2025年6月30日，益方生物十大流通股东中，汇添富创新医药混合A（006113）位 居第四大流通股东，持股996.19万股，为新进股东。中欧医疗健康混合A（003095）位居第五大流通股 东，持股909.24万股，相比上期增加79.05万股。香港中央结算有限公司位居第六大流通股东，持股 805.41万股，为新进股东。睿远成长价值混合A（007119）位居第七大流通股东，持股787.01万股，相 比上期增加56.85万股。鹏华医药科技股票A（001230）退出十大流通股东之列。 今年以来益方生物 ...

Core Viewpoint - Yifang Bio has shown significant stock price fluctuations and performance metrics, indicating both growth potential and recent challenges in the market [1][2]. Group 1: Stock Performance - As of September 30, Yifang Bio's stock price increased by 2.00% to 31.55 CNY per share, with a trading volume of 1.27 billion CNY and a turnover rate of 0.97%, resulting in a total market capitalization of 18.247 billion CNY [1]. - Year-to-date, Yifang Bio's stock price has risen by 137.22%, but it has experienced a decline of 3.58% over the last five trading days and 22.80% over the last 20 days [1]. - The company has appeared on the "Dragon and Tiger List" three times this year, with the most recent instance on July 11, where it recorded a net purchase of 68.8706 million CNY [1]. Group 2: Financial Performance - For the first half of 2025, Yifang Bio reported a revenue of 19.1638 million CNY, reflecting a year-on-year growth of 28.85%, while the net profit attributable to shareholders was -119 million CNY, an increase of 44.25% compared to the previous period [2]. - As of June 30, 2025, the number of shareholders decreased by 7.28% to 9,790, while the average circulating shares per person increased by 7.85% to 40,990 shares [2]. Group 3: Shareholder Composition - As of June 30, 2025, notable institutional shareholders include Huatai-PineBridge Innovation Medicine Mixed A, which is the fourth largest shareholder with 9.9619 million shares, and Central Clearing Hong Kong Limited, which is a new shareholder with 8.0541 million shares [2]. - The fifth largest shareholder, China Europe Medical Health Mixed A, increased its holdings by 790,500 shares to 9.0924 million shares [2].

资料显示，百济神州有限公司位于北京市昌平区中关村生命科学园科学园路30号，成立日期2010年10月 28日，上市日期2021年12月15日，公司主营业务涉及研究、开发、生产以及商业化创新型药物。主营业 务收入构成为：药品销售收入99.10%，合作安排收入0.90%。 百济神州所属申万行业为：医药生物-化学制药-化学制剂。所属概念板块包括：抗癌治癌、H股、百元 股、基金重仓、抗癌药物等。 9月30日，百济神州盘中上涨2.02%，截至10:49，报307.09元/股，成交5.59亿元，换手率1.59%，总市值 4731.27亿元。 资金流向方面，主力资金净流出1907.92万元，特大单买入5861.36万元，占比10.48%，卖出4989.87万 元，占比8.93%；大单买入1.41亿元，占比25.15%，卖出1.68亿元，占比30.12%。 百济神州今年以来股价涨90.72%，近5个交易日涨1.17%，近20日跌5.47%，近60日涨37.62%。 今年以来百济神州已经1次登上龙虎榜，最近一次登上龙虎榜为9月2日。 截至6月30日，百济神州股东户数2.33万，较上期减少3.90%；人均流通股4976股，较上期增 ...

Core Viewpoint - Benda Pharmaceutical's stock has shown a mixed performance in recent months, with a year-to-date increase of 24.99% but a decline of 10.42% over the past 20 days, indicating volatility in its market position [1][2]. Financial Performance - For the first half of 2025, Benda Pharmaceutical reported a revenue of 1.731 billion yuan, reflecting a year-on-year growth of 15.37%. However, the net profit attributable to shareholders decreased by 37.53% to 140 million yuan [2]. - The company has distributed a total of 669 million yuan in dividends since its A-share listing, with 184 million yuan distributed over the past three years [3]. Shareholder and Market Activity - As of June 30, 2025, the number of shareholders increased by 9.97% to 32,100, while the average number of circulating shares per person decreased by 9.08% to 13,064 shares [2]. - The stock's trading activity on September 30, 2023, showed a net inflow of 6.5472 million yuan from major funds, with significant buying and selling activity [1]. Company Overview - Benda Pharmaceutical, established on January 7, 2003, and listed on November 7, 2016, is primarily engaged in the research, production, and sales of pharmaceuticals, with 99.10% of its revenue coming from drug sales [1]. - The company operates within the pharmaceutical and biotechnology sector, focusing on cancer treatment drugs and innovative medicines [1].

Core Viewpoint - The stock of TEBIO has shown a positive trend with a year-to-date increase of 15.02% and a recent rise of 5.63% over the last five trading days, indicating strong market interest and performance [1]. Financial Performance - For the first half of 2025, TEBIO reported a revenue of 1.511 billion yuan, representing a year-on-year growth of 26.96% [2]. - The net profit attributable to shareholders for the same period was 428 million yuan, reflecting a year-on-year increase of 40.60% [2]. Shareholder Information - As of June 30, 2025, the number of shareholders increased to 8,439, up by 13 compared to the previous period [2]. - The average number of circulating shares per shareholder decreased by 11.51% to 48,204 shares [2]. Dividend Distribution - TEBIO has distributed a total of 577 million yuan in dividends since its A-share listing, with 506 million yuan distributed over the last three years [3]. Institutional Holdings - As of June 30, 2025, major institutional shareholders include Huaxia SSE STAR 50 ETF and E Fund SSE STAR 50 ETF, with both increasing their holdings [3].

Company Overview - Teabo Bioengineering Co., Ltd. is located in Xiamen, Fujian Province, established on August 7, 1996, and listed on January 17, 2020. The company specializes in the research, production, and sales of recombinant proteins and long-acting modified drugs [1][2] - The main business revenue composition includes antiviral drugs (86.85%), blood/cancer drugs (12.87%), and other (supplement) (0.27%) [1] Financial Performance - For the first half of 2025, Teabo Bio achieved operating revenue of 1.511 billion yuan, a year-on-year increase of 26.96%, and a net profit attributable to shareholders of 428 million yuan, a year-on-year increase of 40.60% [2] - Since its A-share listing, Teabo Bio has distributed a total of 577 million yuan in dividends, with 506 million yuan distributed over the past three years [2] Stock Performance - As of September 25, Teabo Bio's stock price increased by 2.08%, reaching 83.08 yuan per share, with a total market capitalization of 33.797 billion yuan [1] - Year-to-date, the stock price has risen by 14.20%, with a 4.46% increase over the last five trading days and a 14.94% increase over the last 60 days [1] Shareholder Information - As of June 30, the number of shareholders for Teabo Bio was 8,439, an increase of 13.00% from the previous period, while the average circulating shares per person decreased by 11.51% to 48,204 shares [2] - Among the top ten circulating shareholders, Huaxia SSE Sci-Tech Innovation 50 ETF and E Fund SSE Sci-Tech Innovation 50 ETF increased their holdings [2]

9月25日，泰恩康盘中下跌2.07%，截至10:18，报33.66元/股，成交6341.35万元，换手率0.62%，总市值 143.22亿元。 泰恩康所属申万行业为：医药生物-化学制药-化学制剂。所属概念板块包括：合成生物、创新药、眼科 概念、抗癌药物、抗癌治癌等。 截至6月30日，泰恩康股东户数1.09万，较上期减少33.05%；人均流通股27747股，较上期增加49.36%。 2025年1月-6月，泰恩康实现营业收入3.47亿元，同比减少12.23%；归母净利润3708.48万元，同比减少 56.75%。 泰恩康今年以来股价涨127.57%，近5个交易日跌7.09%，近20日跌4.62%，近60日跌9.39%。 资料显示，广东泰恩康医药股份有限公司位于广东省汕头市龙湖区泰山北路万吉南二街8号A幢，成立 日期1999年1月22日，上市日期2022年3月29日，公司主营业务涉及代理运营及研发、生产、销售医药产 品、医疗器械、卫生材料并提供医药技术服务与技术转让等。主营业务收入构成为：医药代理 65.16%，医药制造31.70%，医药技术服务及技术转让2.97%，其他(补充)0.17%。 分红方面，泰恩康A股上 ...